Government-Owned Inventions; Availability for Licensing, 77875-77876 [2024-21742]
Download as PDF
<![CDATA[
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; HIV
COMORBIDITIES AND RESERVOIRS.
Date: November 8, 2024.
Time: 10:00 a.m. to 5:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
NIDDK, Democracy II, Suite 7000A, 6707
Democracy Boulevard, Bethesda, MD 20892
(Virtual Meeting).
Contact Person: Maria E. Davila-Bloom,
Ph.D., Scientific Review Officer, National
Institute of Diabetes and Digestive and
Kidney Diseases, National Institutes of
Health, 6707 Democracy Boulevard, Rm.
7017, Bethesda, MD 20892–5452, (301) 594–
7637, davila-bloomm@extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
mail.nih.gov. Licensing information
may be obtained by communicating
with the Technology Transfer and
Intellectual Property Office, National
Institute of Allergy and Infectious
Diseases, 5601 Fishers Lane, Rockville,
MD 20852: tel. 301–496–2644. A signed
Confidential Disclosure Agreement will
be required to receive copies of
unpublished information related to the
invention.
SUPPLEMENTARY INFORMATION:
Technology description follows:
Name of Committee: National Institute of
General Medical Sciences Special Emphasis
Panel; Review of Support for Research
Excellence (SuRE) Program and Support for
Research Excellence—First Independent
Research (SuRE-First) Award (R16).
Date: October 31–November 1, 2024.
Time: 10:00 a.m. to 6:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health,
National Institute of General Medical
Sciences, Natcher Building, 45 Center Drive,
Bethesda, Maryland 20892 (Virtual Meeting).
Contact Person: John J. Laffan, Ph.D.,
Scientific Review Officer, Office of Scientific
Review, National Institute of General Medical
Sciences, National Institutes of Health,
Natcher Building, 45 Center Drive, Room
3AN18J, Bethesda, Maryland 20892, 301–
594–2773, laffanjo@mail.nih.gov.
(Catalogue of Federal Domestic Assistance
Program No. 93.859, Biomedical Research
and Research Training, National Institutes of
Health, HHS)
Monoclonal Antibodies That Bind to
the Underside of Influenza Viral
Neuraminidase
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21740 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
Government-Owned Inventions;
Availability for Licensing
[FR Doc. 2024–21736 Filed 9–23–24; 8:45 am]
ACTION:
AGENCY:
National Institutes of Health,
HHS.
Notice.
The invention listed below is
owned by an agency of the U.S.
Government and is available for
licensing to achieve expeditious
commercialization of results of
federally-funded research and
development. Foreign patent
applications are filed on selected
inventions to extend market coverage
for companies and may also be available
for licensing.
FOR FURTHER INFORMATION CONTACT:
Haiqing Li at 240–627–3708, or lihai@
SUMMARY:
lotter on DSK11XQN23PROD with NOTICES1
National Institutes of Health
National Institute of General Medical
Sciences; Notice of Closed Meeting
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
VerDate Sep<11>2014
18:46 Sep 23, 2024
Jkt 262001
PO 00000
Frm 00065
Fmt 4703
Description of Technology
Current influenza vaccines mainly
induce antibodies against the surface
glycoprotein hemagglutinin (HA) that
block viral attachment to its host
receptors and viral membrane fusion to
the host cell. The immunodominant
head region of HA undergoes antigenic
drift and antibodies directed to the head
confer little cross-protections between
strains or subtypes.
Researchers at the Vaccine Research
Center of the National Institute of
Allergy and Infectious Diseases have
identified human monoclonal
antibodies that each bind distinct
epitopes on the less abundant yet
critical viral surface glycoprotein
neuraminidase (NA). These antibodies,
isolated from convalescent individuals
with confirmed influenza A H3N2
infection, inhibit viral propagation of a
wide range of human H3N2, swineorigin variant H3N2, and H2N2 viruses
and confer pre-exposure and postexposure protection from lethal H3N2
infection in mice. Cryo-electron
microscopy revealed that two of these
antibodies bind non-overlapping
epitopes covering the underside of the
NA head, thus defining a potential
vaccine target.
This technology is available for
licensing for commercial development
in accordance with 35 U.S.C. 209 and 37
CFR part 404.
Potential Commercial Applications
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
77875
Sfmt 4703
• Prevention or treatment of influenza
infection
• Testing influenza antigens
Competitive Advantages
• Improved breadth of protection
relative to influenza HA-targeting
antibodies
Development Stage: Preclinical.
Inventors: Masaru Kanekiyo (NIAID),
Sarah Andrews (NIAID), Julia
Lederhofer (NIAID), Yaroslav Tsybovsky
(Leidos Biomedical Research).
E:\FR\FM\24SEN1.SGM
24SEN1
77876
Federal Register / Vol. 89, No. 185 / Tuesday, September 24, 2024 / Notices
Publications: Protective human
monoclonal antibodies target conserved
sites of vulnerability on the underside of
influenza virus neuraminidase.
Lederhofer, Julia et al. Immunity,
Volume 57, Issue 3, 574–586.e7.
Intellectual Property: PCT/US2023/
071194 filed 28 July 2023 (NIH Ref. No.
E–177–2022).
Licensing Contact: To license this
technology, please contact Haiqing Li at
240–627–3708, or lihai@mail.nih.gov,
and reference E–177–2022.
Dated: September 18, 2024.
Christopher M. Kornak,
Acting Deputy Director, Technology Transfer
and Intellectual Property Office, National
Institute of Allergy and Infectious Diseases.
[FR Doc. 2024–21742 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
National Institutes of Health
National Institute of Diabetes and
Digestive and Kidney Diseases; Notice
of Closed Meeting
lotter on DSK11XQN23PROD with NOTICES1
Pursuant to section 1009 of the
Federal Advisory Committee Act, as
amended, notice is hereby given of the
following meeting.
The meeting will be closed to the
public in accordance with the
provisions set forth in sections
552b(c)(4) and 552b(c)(6), title 5 U.S.C.,
as amended. The grant applications and
the discussions could disclose
confidential trade secrets or commercial
property such as patentable material,
and personal information concerning
individuals associated with the grant
applications, the disclosure of which
would constitute a clearly unwarranted
invasion of personal privacy.
Name of Committee: National Institute of
Diabetes and Digestive and Kidney Diseases
Special Emphasis Panel; Time-Sensitive
Obesity review.
Date: October 29, 2024.
Time: 2:00 p.m. to 3:00 p.m.
Agenda: To review and evaluate grant
applications.
Place: National Institutes of Health, NIDDK
Democracy II, Suite 7000A, 6707 Democracy
Boulevard, Bethesda, MD 20892 (Virtual
Meeting).
Contact Person: Michele L. Barnard, Ph.D.,
Scientific Review Officer, National Institute
of Diabetes and Digestive and Kidney,
National Institute of Health, 6707 Democracy
Boulevard, Rm. 7353, Bethesda, MD 20892–
2542, (301) 594–8898, barnardm@
extra.niddk.nih.gov.
(Catalogue of Federal Domestic Assistance
Program Nos. 93.847, Diabetes,
Endocrinology and Metabolic Research;
93.848, Digestive Diseases and Nutrition
VerDate Sep<11>2014
18:07 Sep 23, 2024
Jkt 262001
Research; 93.849, Kidney Diseases, Urology
and Hematology Research, National Institutes
of Health, HHS)
Dated: September 18, 2024.
Miguelina Perez,
Program Analyst, Office of Federal Advisory
Committee Policy.
[FR Doc. 2024–21737 Filed 9–23–24; 8:45 am]
BILLING CODE 4140–01–P
DEPARTMENT OF HEALTH AND
HUMAN SERVICES
Substance Abuse and Mental Health
Services Administration
Agency Information Collection
Activities: Submission for OMB
Review; Comment Request
Periodically, the Substance Abuse and
Mental Health Services Administration
(SAMHSA) will publish a summary of
information collection requests under
OMB review, in compliance with the
Paperwork Reduction Act (44 U.S.C.
chapter 35). To request a copy of these
documents, call the SAMHSA Reports
Clearance Officer on (240) 276–0361.
Proposed Project: New: The Center for
Substance Abuse Prevention Online
Reporting Tool and Grant Programmatic
Progress Report to replace Division of
State Programs—Management Reporting
Tool (DSP–MRT) (OMB No. 0930–0354).
The Substance Abuse and Mental
Health Services Administration’s
(SAMHSA), Center for Substance Abuse
Prevention (CSAP) is requesting
approval from the Office of Management
and Budget (OMB) to monitor CSAP
discretionary grant programs through
administration of a suite of data
collection instruments for grant
compliance and programmatic
performance monitoring.
This package describes the data
collection activities and proposed
instruments. Grant compliance
monitoring will be conducted via a
single data collection instrument to be
completed by all CSAP discretionary
grant recipients. Programmatic
performance monitoring will be
conducted via a suite of data collection
instruments with each instrument
tailored to a specific CSAP discretionary
program. This request for data collection
will replace OMB No. 0930–0354:
Division of State Programs—
Management Reporting Tool.
CSAP intends to monitor six grant
programs through this data collection
effort:
• Strategic Prevention Framework—
Partnerships for Success (SPF–PFS): The
purpose of the SPF–PFS program is to
help reduce the onset and progression of
PO 00000
Frm 00066
Fmt 4703
Sfmt 4703
substance misuse and its related
problems by supporting the
development and delivery of state and
community substance misuse
prevention and mental health
promotion services. This program is
intended to promote substance use
prevention throughout a state
jurisdiction for individuals and families
by building and expanding the capacity
of local community prevention
providers to implement evidence-based
programs. In addition, the program is
intended to expand and strengthen the
capacity of local community prevention
providers to implement evidence-based
prevention programs. With this
program, SAMHSA aims to strengthen
state and community level prevention
capacity to identify and address local
substance use prevention concerns,
such as underage drinking, marijuana,
tobacco, electronic cigarettes, opioids,
methamphetamine, and heroin.
• Sober Truth on Preventing
Underage Drinking (STOP Act): The
purpose of this program is to prevent
and reduce alcohol use among youth
and young adults ages 12–20 in
communities throughout the United
States through evidence-based
screening, programs and curricula, brief
intervention strategies, consistent policy
enforcement, and environmental
changes that limit underage access to
alcohol as authorized by 42 U.S.C.
290bb–25b. The program aims to: (1)
address norms regarding alcohol use by
youth, (2) reduce opportunities for
underage drinking, (3) create changes in
underage drinking enforcement efforts,
(4) address penalties for underage use,
and/or (5) reduce negative consequences
associated with underage drinking.
• Strategic Prevention Framework for
Prescription Drugs (SPF Rx): The
purpose of the SPF Rx grant program is
to provide resources to help prevent and
address prescription drug misuse within
a State or locality. The program is
designed to raise awareness about the
dangers of sharing medications as well
as the risks of fake or counterfeit pills
purchased over social media or other
unknown sources, and work with
pharmaceutical and medical
communities on the risks of
overprescribing. Whether addressed at
the state level or by an informed
community-based organization, the SPF
Rx program will raise community
awareness and bring prescription
substance misuse prevention activities
and education to schools, communities,
parents, prescribers, and their patients.
In addition, grant recipients will be
required to track reductions in opioid
related overdoses and incorporate
relevant prescription and overdose data
E:\FR\FM\24SEN1.SGM
24SEN1
]]>Agencies
[Federal Register Volume 89, Number 185 (Tuesday, September 24, 2024)]
[Notices]
[Pages 77875-77876]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2024-21742]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
National Institutes of Health
Government-Owned Inventions; Availability for Licensing
AGENCY: National Institutes of Health, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The invention listed below is owned by an agency of the U.S.
Government and is available for licensing to achieve expeditious
commercialization of results of federally-funded research and
development. Foreign patent applications are filed on selected
inventions to extend market coverage for companies and may also be
available for licensing.
FOR FURTHER INFORMATION CONTACT: Haiqing Li at 240-627-3708, or
[email protected]. Licensing information may be obtained by
communicating with the Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases, 5601
Fishers Lane, Rockville, MD 20852: tel. 301-496-2644. A signed
Confidential Disclosure Agreement will be required to receive copies of
unpublished information related to the invention.
SUPPLEMENTARY INFORMATION: Technology description follows:
Monoclonal Antibodies That Bind to the Underside of Influenza Viral
Neuraminidase
Description of Technology
Current influenza vaccines mainly induce antibodies against the
surface glycoprotein hemagglutinin (HA) that block viral attachment to
its host receptors and viral membrane fusion to the host cell. The
immunodominant head region of HA undergoes antigenic drift and
antibodies directed to the head confer little cross-protections between
strains or subtypes.
Researchers at the Vaccine Research Center of the National
Institute of Allergy and Infectious Diseases have identified human
monoclonal antibodies that each bind distinct epitopes on the less
abundant yet critical viral surface glycoprotein neuraminidase (NA).
These antibodies, isolated from convalescent individuals with confirmed
influenza A H3N2 infection, inhibit viral propagation of a wide range
of human H3N2, swine-origin variant H3N2, and H2N2 viruses and confer
pre-exposure and post-exposure protection from lethal H3N2 infection in
mice. Cryo-electron microscopy revealed that two of these antibodies
bind non-overlapping epitopes covering the underside of the NA head,
thus defining a potential vaccine target.
This technology is available for licensing for commercial
development in accordance with 35 U.S.C. 209 and 37 CFR part 404.
Potential Commercial Applications
Prevention or treatment of influenza infection
Testing influenza antigens
Competitive Advantages
Improved breadth of protection relative to influenza HA-
targeting antibodies
Development Stage: Preclinical.
Inventors: Masaru Kanekiyo (NIAID), Sarah Andrews (NIAID), Julia
Lederhofer (NIAID), Yaroslav Tsybovsky (Leidos Biomedical Research).
[[Page 77876]]
Publications: Protective human monoclonal antibodies target
conserved sites of vulnerability on the underside of influenza virus
neuraminidase. Lederhofer, Julia et al. Immunity, Volume 57, Issue 3,
574-586.e7.
Intellectual Property: PCT/US2023/071194 filed 28 July 2023 (NIH
Ref. No. E-177-2022).
Licensing Contact: To license this technology, please contact
Haiqing Li at 240-627-3708, or [email protected], and reference E-177-
2022.
Dated: September 18, 2024.
Christopher M. Kornak,
Acting Deputy Director, Technology Transfer and Intellectual Property
Office, National Institute of Allergy and Infectious Diseases.
[FR Doc. 2024-21742 Filed 9-23-24; 8:45 am]
BILLING CODE 4140-01-P
